Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

7.7%

1 terminated/withdrawn out of 13 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

8%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

7 recruiting

Enrollment Performance

Analytics

Phase 1
11(84.6%)
Phase 3
1(7.7%)
Phase 2
1(7.7%)
13Total
Phase 1(11)
Phase 3(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (13)

Showing 13 of 13 trials
NCT05551507Phase 1Recruiting

IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer

Role: lead

NCT05982522Phase 1Withdrawn

IN10018 Combination Therapy in Previously-treated Solid Tumors

Role: lead

NCT06166836Phase 1Active Not Recruiting

a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors

Role: lead

NCT07174908Phase 3Recruiting

A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation

Role: lead

NCT07441174Phase 1Recruiting

IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors

Role: lead

NCT04109456Phase 1Completed

IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

Role: lead

NCT05830539Phase 1Completed

IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients

Role: lead

NCT05827796Phase 1Recruiting

IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer

Role: lead

NCT05994131Phase 1Recruiting

IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC

Role: lead

NCT06030258Phase 1Recruiting

IN10018 Combination Therapy in Treatment-naïve ES-SCLC

Role: lead

NCT06014528Phase 2Recruiting

IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer

Role: lead

NCT05379946Phase 1Active Not Recruiting

Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors

Role: collaborator

NCT05327231Phase 1Completed

IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma

Role: lead

All 13 trials loaded